Editorial Material
Oncology
Sun Min Lim, Chang Gon Kim, Jii Bum Lee, Byoung Chul Cho
Summary: This article highlights the potential of patritumab deruxtecan as a valuable therapeutic agent for previously treated EGFR-mutant NSCLC, based on early clinical data. It emphasizes the ubiquitous expression of HER3 in EGFR-mutant NSCLC, making it an important therapeutic target.
Article
Respiratory System
Bing Han, Yanrong Kang, Haiji Wang, Jian Wang, Rong Shen, Shuai Liu, Lu Lu, Zhigang Sun, Nan Zhang
Summary: The study evaluated the clinical efficacy and safety of Endostar in patients with EGFR-TKI-resistant NSCLC, showing promising treatment outcomes and survival results for this type of lung cancer patients. Endostar was found to be effective and well tolerated in advanced NSCLC patients, with a disease control rate of 79.4% and no treatment-associated deaths observed.
BMC PULMONARY MEDICINE
(2023)
Article
Oncology
Si Sun, Chang Liu, Chunyan Duan, Songxia Yu, Qiao Zhang, Nana Xu, Bo Yu, Xianghua Wu, Jialei Wang, Xingjiang Hu, Hui Yu
Summary: ICIs combined with chemotherapy can significantly improve progression-free survival in NSCLC patients with EGFR mutations. According to the study results, the median PFS in the ICI combined chemotherapy group is longer than that in the ICI monotherapy group, and it shows the best survival outcome in terms of 12-month survival rate and PFS. The safety profile of the combination therapy is similar to previously reported studies of chemotherapy combined with checkpoint inhibitors.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Kenichi Koyama, Satoru Miura, Satoshi Watanabe, Satoshi Shoji, Jun Koshio, Yoshiki Hayashi, Daisuke Ishikawa, Ko Sato, Takao Miyabayashi, Masaaki Okajima, Takeshi Ota, Tomohiro Tanaka, Naoya Matsumoto, Hideyuki Kuriyama, Tetsuya Abe, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Hiroshi Tanaka, Toshiaki Kikuchi
Summary: Rebiopsy is crucial in selecting optimal treatments for NSCLC patients with acquired resistance mutations, with a high implementation rate of 90.8% observed in Japanese clinical practice. Obtaining histological or cytological tissue samples during rebiopsy may contribute to improving the detection rate of the T790M mutation.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, Research & Experimental
Suntae Kim, Jang Su Jeon, Yong June Choi, Ga Hee Baek, Sang Kyum Kim, Keon Wook Kang
Summary: The heterogeneity of glutamine metabolism in EGFR-TKI-resistant lung cancer cells was evaluated in this study. It was found that CB-839, a specific GLS inhibitor, can effectively inhibit glutamine metabolism and exert enhanced anti-proliferating effects on acquired EGFR-TKI-resistant lung cancer cells.
Review
Oncology
Jingwei Li, Peiyi Li, Jun Shao, Shufan Liang, Yuntian Wan, Qiran Zhang, Changshu Li, Yalun Li, Chengdi Wang
Summary: This review summarizes the potential mechanisms of noncoding RNAs in EGFR TKI-resistant lung cancer and their clinical applications, and highlights the barriers that need to be addressed.
Article
Chemistry, Medicinal
Haojie Dong, Xiuquan Ye, Yasheng Zhu, Hao Shen, Hongtao Shen, Weijiao Chen, Minghui Ji, Mingming Zheng, Keren Wang, Zeyu Cai, Haopeng Sun, Yibei Xiao, Peng Yang
Summary: In this study, a series of Osimertinib derivatives were designed as fourth-generation inhibitors targeting Osimertinib-resistant NSCLC. The top candidate D51 showed potent inhibition against EGFR mutants, selectivity against wild-type forms, and favorable in vivo druggability.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Review
Oncology
Xiaoshun Shi, Xiaoying Dong, Jianxue Zhai, Xiguang Liu, Di Lu, Zhen Ni, Hua Wu, Kaican Cai
Summary: Neoadjuvant EGFR-TKIs showed objective responses in approximately half of EGFR-sensitive NSCLC patients with a tolerable adverse effect profile. The impact of neoadjuvant EGFR-TKIs on survival remains inconclusive, and further evidence is needed to validate its favorable impact on NSCLC. The efficacy of neoadjuvant next-generation EGFR-TKIs in clinical trials remains unclear.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Jacqulyne P. Robichaux, Xiuning Le, R. S. K. Vijayan, J. Kevin Hicks, Simon Heeke, Yasir Y. Elamin, Heather Y. Lin, Hibiki Udagawa, Ferdinandos Skoulidis, Hai Tran, Susan Varghese, Junqin He, Fahao Zhang, Monique B. Nilsson, Lemei Hu, Alissa Poteete, Waree Rinsurongkawong, Xiaoshan Zhang, Chenghui Ren, Xiaoke Liu, Lingzhi Hong, Jianjun Zhang, Lixia Diao, Russell Madison, Alexa B. Schrock, Jennifer Saam, Victoria Raymond, Bingliang Fang, Jing Wang, Min Jin Ha, Jason B. Cross, Jhanelle E. Gray, John Heymach
Summary: The study characterized the mutational landscape in 16,715 patients with EGFR-mutant NSCLC and established the structure-function relationship of EGFR mutations on drug sensitivity. EGFR mutations can be separated into four distinct subgroups based on sensitivity and structural changes, predicting patient outcomes following treatment with EGFR inhibitors better than traditional exon-based groups. This structure-based approach delineates functional groups of EGFR mutations that can effectively guide treatment choices and suggest potential improvement in prediction of drug sensitivity to targeted therapies in oncogenes with diverse mutations.
Review
Pharmacology & Pharmacy
Xiaoyu Qian, Xiaodan Guo, Ting Li, Wei Hu, Lin Zhang, Caisheng Wu, Feng Ye
Summary: ICI monotherapy did not improve the overall survival (OS) or progression-free survival (PFS) of patients with EGFR-TKI-resistant NSCLC. However, ICI-based combination therapy showed better PFS and objective response rate (ORR) compared to conventional chemotherapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Pasi A. Janne, Christina Baik, Wu-Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A. Yu
Summary: HER3-DXd shows clinical activity in EGFR TKI-resistant lung cancer, regardless of resistance mechanisms, providing a new approach to treat drug-resistant cancers.
Article
Oncology
Sonia A. Patel, Monique B. Nilsson, Yan Yang, Xiuning Le, Hai T. Tran, Yasir Y. Elamin, Xiaoxing Yu, Fahao Zhang, Alissa Poteete, Xiaoyang Ren, Li Shen, Jing Wang, Seyed Javad Moghaddam, Tina Cascone, Michael Curran, Don L. Gibbons, John Heymach
Summary: The study investigates the role of IL6 in patients with EGFR-mutant NSCLC. It finds that IL6 is upregulated in EGFR-mutant tumors and suppresses immune function. Blockade of IL6 enhances anti-tumor immunity and the efficacy of PD-1 inhibitors.
CLINICAL CANCER RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Yaming Liu, Xianming Ge, Jinlong Pang, Yuhan Zhang, Hao Zhang, Hongyan Wu, Fangtian Fan, Hao Liu
Summary: The study revealed that in non-small cell lung cancer cells, EGFR mutations lead to increased expression of glutamine transporter (SLC1A5), thereby enhancing glutamine metabolism and activating EGFR downstream signals, resulting in increased resistance to EGFR-tyrosine kinase inhibitors.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Yuankai Shi, Baolan Li, Lin Wu, Yueyin Pan, Zhijie Pan, Yunpeng Liu, Yun Fan, Yinghua Ji, Jian Fang, Qin Shi, Jianhua Shi, Hongjun Gao, Yanping Hu, Xiang Wang, Zhiyong He, Rui Ma, Yu Zhang, Da Jiang, Yuansong Bai, Yi Zhang, Linian Huang, Tong Zhou, Hailong Liu, Daqing Wang, Qinglian Wen, Gongyan Chen, Aimin Zang, Xiuwen Wang, Xinri Zhang, Jianbing Hu, Runxiang Yang, Guojun Zhang, Kangsheng Gu, Lin Wang, Qiming Wang, Zonghui Wei, Zeng Li, Hongda Lu, Helong Zhang, Hongyu Chen, Tingting Song
Summary: This study evaluated the efficacy and safety of Limertinib in patients with locally advanced or metastatic EGFR T790M-mutated NSCLC. The results showed that Limertinib demonstrated promising efficacy and an acceptable safety profile in these patients.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Review
Oncology
Yan Chen, Zijun Chen, Rui Chen, Cheng Fang, Chu Zhang, Mei Ji, Xin Yang
Summary: The rapid development of molecular targeted therapy brings hope to patients with advanced non-small-cell lung cancer. However, drug resistance occurs during EGFR-TKI treatment. Osimertinib shows a favorable prognosis, but acquired resistance is still a challenge. PD-1 and PD-L1 inhibitors have made progress, especially in patients with no actionable mutations. This review summarizes the relationship between EGFR mutations and PD-L1 expression and important clinical studies on immunotherapy-inhibitor-based treatment in EGFR-TKI-resistant NSCLC patients.
